Страница 1 от 123 резултата
OBJECTIVE
A systematic review and meta-analysis of dyslipidemia and diabetic macular edema (DME).
CONCLUSIONS
Diabetic macular edema causes impairment of vision in patients with diabetes, and dyslipidemia has been reported as a risk factor for its development. A systematic review with a
Hyperreflective foci (HF), detected in the retina of diabetic patients, suggest the presence of microglial activation and migration, while controversies still remain for the origin of HF to be precursors of hard exudates. We investigated the presence of HF and their association with Retinal vein occlusion (RVO) is an obstruction of the retinal venous system, and macular edema (ME) is a complication of RVO that can lead to blindness. The Canadian incidence of visual impairment (VI) due to ME secondary to RVO is unknown. This observational, retrospective study used records from
BACKGROUND
In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab).
METHODS
We retrospectively
Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM) and is considered as the leading cause of visual impairment in working-aged adults worldwide. Dyslipidemia has been associated with DR, but not with progression to the proliferative form of DR, although the
OBJECTIVE
To determine the efficacy of atorvastatin in reducing hard exudates and diabetic macular edema.
METHODS
An uncontrolled clinical case series included 18 eyes with diabetic maculopathy and an elevated baseline lipid profile. All patients were treated with atorvastatin. Ophthalmologic
To compare serum and aqueous humor (AH) vitamin D levels between the patients with diabetic macular edema (DME) and controls.A total of 65 subjects (30 DME, 35 control) were included. One-third of the control group had hypertension, dyslipidemia, or Secondary amyloidosis is the most frequent form of the systemic amyloidosis around the world. Data on frequency and nature of dyslipidemia in patients with secondary amyloidosis are not conclusive. We evaluated the lipid abnormalities and their association with clinical and laboratory
OBJECTIVE
To report on a patient with niacin-induced cystic maculopathy that resolved with dosage decrease, not discontinuation, of niacin therapy for dyslipidemia.
METHODS
Retrospective case report. The patient was being followed for vision changes, but his niacin therapy was managed
It is known that clinic blood pressure (BP), gender, cigarette smoking, dyslipidemia, anemia and thiazolidenediones (TZD) treatment are predictors for clinically significant diabetic macula edema (CSDME). We examined a most risky factor for CSDME in Japanese patients with type 2 diabetes mellitus
OBJECTIVE
To study the relationship between systemic pro-inflammatory factors and macular structural response to intravitreal bevacizumab for diabetic macular edema (DME).
METHODS
Prospective study including 30 cases with DME, treated with bevacizumab and a minimum follow-up of 6 months. All cases
BACKGROUND
Statins, although the treatment of choice for dyslipidemia after heart transplantation (HT), are not always well tolerated or effective. In such cases, administration of ezetimibe may be useful.
OBJECTIVE
The aim of this study was to assess the efficacy and safety of ezetimibe, with or
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia.
OBJECTIVE
The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice.
METHODS
This was an observational, multicenter, single-arm study.
Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse after successful treatment. DME is a complex pathological process
OBJECTIVE
To report a case series, whereby we encountered a transient increase in retinal cotton wool spots (CWS) following anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).
METHODS
Eighteen eyes were